Alliance Global raised the firm’s price target on Capricor Therapeutics (CAPR) to $51 from $48 and keeps a Buy rating on the shares. Capricor delivered an upbeat Q4 update, highlighting FDA acceptance of its updated BLA for Deramiocel with a new August 22 PDUFA date, along with additional positive Phase 3 HOPE-3 data supporting clinical benefit in Duchenne muscular dystrophy, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics price target raised to $63 from $50 at B. Riley
- Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler
- Capricor Therapeutics reports Q4 EPS (62c), consensus (55c)
- Capricor Therapeutics options imply 4.2% move in share price post-earnings
- Deramiocel’s De‑Risked Path to Approval and Expanded DMD Opportunity Underpin Buy on CAPR